Up 50%: Merrimack Pharmaceuticals' Groundbreaking News

Shares in Merrimack Pharmaceuticals (NASDAQ: MACK) gained over 50% today on great news regarding a phase 3 trial for its MM-398 drug for pancreatic cancer. In combination with 5-flouroacil and leucovorin, MM-398 generated a 1.9 month lift in overall survival (from 4.2 months to 6.1 months) for pancreatic cancer patients compared to patients just taking the other two drugs. This was particularly good news considering that MM-398 had previously failed a trial as a monotherapy.

Of course, the drug still needs to go through the FDA approval process, but if it hits the market, what are its chances of grabbing market share in this hard-to-treat cancer? In the video below, Motley Fool health care analysts David Williamson and Michael Douglass discuss the drug and its opportunities if approved.

Can Merrimack shares keep up with this top stock in 2014?
Give me five minutes and I'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks 1 stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.

Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2940345, ~/Articles/ArticleHandler.aspx, 9/3/2015 11:10:44 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Michael Douglass

As the Motley Fool's Health Care Editor/Analyst, I focus on all things health care -- although my greatest interest is in the megatrends reshaping the American health care system, including the Affordable Care Act, Accountable Care Organizations, a shifting regulatory landscape, and the new drug discoveries fundamentally changing disease management and treatment.

Today's Market

updated Moments ago Sponsored by:
DOW 16,531.43 180.05 1.10%
S&P 500 1,973.68 24.82 1.27%
NASD 4,790.72 40.74 0.86%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/3/2015 10:54 AM
MACK $10.34 Up +0.19 +1.87%
Merrimack Pharmace… CAPS Rating: ***
CELG $120.33 Up +0.75 +0.63%
Celgene CAPS Rating: *****